Loading...
XNASCLSD
Market cap70mUSD
Jan 17, Last price  
0.93USD
1D
0.53%
1Q
-19.14%
Jan 2017
-89.60%
IPO
-86.83%
Name

Clearside Biomedical Inc

Chart & Performance

D1W1MN
XNAS:CLSD chart
P/E
—
P/S
8.57
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.00%
Rev. gr., 5y
207.34%
Revenues
8m
+519.89%
0000520,000345,00030,0002,173,0007,894,00029,575,0001,327,0008,226,000
Net income
-32m
L-4.66%
-3,931,000-7,254,000-10,189,000-17,639,000-25,882,000-58,975,000-82,818,000-30,559,000-18,030,000376,000-34,071,343-32,485,000
CFO
-18m
L+35.69%
-3,176,000-6,839,000-9,124,000-13,902,000-22,709,000-51,083,000-79,200,000-27,068,000-13,120,000-10,733,000-13,365,000-18,135,000
Earnings
Mar 10, 2025

Profile

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
URL
https://clearsidebio.com/
IPO date
Jun 02, 2016
Employees
36
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,226
519.89%
1,327
-95.51%
Cost of revenue
33,070
31,604
Unusual Expense (Income)
NOPBT
(24,844)
(30,277)
NOPBT Margin
Operating Taxes
1,124
Tax Rate
NOPAT
(24,844)
(31,401)
Net income
(32,485)
-4.66%
(34,071)
-9,161.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,666
695
BB yield
-2.30%
-1.03%
Debt
Debt current
728
349
Long-term debt
43,650
2,221
Deferred revenue
Other long-term liabilities
480
33,041
Net debt
15,458
(45,718)
Cash flow
Cash from operating activities
(18,135)
(13,365)
CAPEX
(1,777)
(246)
Cash from investing activities
(1,777)
(246)
Cash from financing activities
414
31,333
FCF
(26,837)
(25,219)
Balance
Cash
28,920
48,258
Long term investments
30
Excess cash
28,509
48,222
Stockholders' equity
(320,860)
(288,377)
Invested Capital
348,793
334,246
ROIC
ROCE
EV
Common stock shares outstanding
61,807
60,205
Price
1.17
4.46%
1.12
-59.27%
Market cap
72,314
7.24%
67,429
-59.07%
EV
87,772
21,711
EBITDA
(24,777)
(30,132)
EV/EBITDA
Interest
9,360
3,339
Interest/NOPBT